CDK4 and breast cancer: The importance of the overexpression/amplification of CCNE1 (encodes cyclin E1) and non-canonical activation of cyclin D-CDK2 has also been suggested in preclinical studies using long-term CDK4/6i-resistant cell models, including in BC models29–31.